nd ESTRO Forum 2013 S59 summary of mean and minimum percentage of detectors/pixels passing with γ<1 is given in Table 1 for 3%/3mm, 3%/2mm and 2%/2mm for each system. A lower number indicates greater measurement sensitivity. Additionally, ρ c , is given for the comparison between measured and predicted γ for each system in Table 1 . The Delta4 was found to be the most sensitive system overall but with the lowest ρ c , indicating lower agreement with the predicted γ. The remaining systems had comparable sensitivity to each other. The 2D-Array and ArcCHECK measurements exhibited better statistical agreement with the predicted γ. Conclusions: It is important to understand the sensitivity and limitations of the gamma index analysis combined with the equipment in use. For the same passing criteria, different devices and software combinations exhibit varying sensitivity and agreement with the predicted analysis. Purpose/Objective: The use of volumetric arc therapy (VMAT) is growing rapidly for many radio-therapy treatments due to its ability to quickly deliver highly conformal dose distributions. There has also been an increasing interest to use high dose rate flattening filter free (FFF) beams as inverse planning systems do not require flat, evenly distributed beams. Such fast and complex treatments should be accompanied by robust verification. Methods to calibrate electronic portal imaging device (EPID) dosimetry has been previously documented for step and shoot stereotactic treatments such as Intensity modulated radiotherapy (IMRT) using only flattened beams and only on the integrated fraction or beam. The aim of this work is to provide a time-dependent dose verification method for VMAT that can be used with flattened or FFF pre-treatment beams via a general calibration model for amorphous silicon (a-Si) EPIDs. Materials and Methods: The general calibration model was created using a Varian Truebeam, equipped with an as1000 EPID, for each unique energy spectrum 6MV, 10MV, 6MV-FFF, 10MV-FFF taking the field size, off axis ratio, and penumbral spectral changes of the beam into account. Also included in the model are the EPID specific corrections such as pixel sensitivity, support arm back scatter, and image ghosting. As planned VMAT treatments are separated into control points (CPs) for optimization, measured images are also separated into the same time intervals so that direct verification of prediction images can be performed. Linac log files were used to synchronize measurement and prediction. The dosimetric accuracy of the calibration model was determined for a range of treatment conditions. Measured and predicted 2D control point doses were compared using a gamma evaluation with criterion of 3% 3mm.
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Results:
Out of 20 VMAT plans tested that passed the clinical action level for integrated dose (95% in field area with gamma within 3% 3mm), the poorest performing plan contained 4.2% in-field area failing the gamma criterion when delivered with a flattened beam and 4.0% when delivered with a FFF beam. The same plan analysed per control point revealed that 18%, and 17% of the arc contained failure areas larger than 5% when delivered with a flattened and FFF beam respectively. Analysing VMAT treatments per control point reveals deviations from predictions during the arc that are averaged in integrated doses, and therefore undetectable. For repeated deliveries of the same plan, the highest dose variation in delivery of FFF plans was ~0.5% compared to 0.2% for flattened beams.
Conclusions:
The EPID calibration model allows verification of pretreatment VMAT doses for both flattened and unflattened beams in a time-dependent manner. Purpose/Objective: To develop a method for pre-treatment verification of VMAT dose delivery as a function of gantry angle using an EPID. Materials and Methods: The method: 1) compares MV EPID image frames with predicted images at the delivered gantry angles; 2) uses an accurate physics-based model that models the EPID images from the planned MLC motions and gantry angles; 3) acquires EPID image frames using an ancillary frame-grabber system that captures all acquired image frames without frame loss; 4) determines the gantry angle for the MV image from an accurate encoder-derived gantry angle tagged to the header of kV frames (acquired simultaneously with the frame-grabber); 5) accounts for small variations in delivered gantry angle by a search of a small sub-arc of angles centred on the imaged angle to synchronise the measured and predicted images; and 6) performs Chi comparison of measured and predicted images giving these analyses as a function of gantry angle. The method also classifies images without significant signal due to beam-holds from low signal images using the scatter signal to the kV imager, and we have optimised the acquisition frame-rate to reduce image artefact due to beam pulse dropping during VMAT delivery.
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Results:
The physics-based model was tested for agreement with EPID images integrated over the entire treatment with average Chi pass rates at 2%,2mm of 99.2% (10% threshold). The accuracy of the gantry angle method was tested using images of a phantom to encode the true angle on the MV image, with agreement (1 SD) of 0.1 degrees. Chi analysis results as a function of angle were assessed for 10 prostate patient deliveries. Approximately 650 images were captured during each arc delivery, resulting in ~ 100 Chi maps, each representing a 3.5 degree sub-arc. All Chi pass-rates were greater than 90% at 3%,3mm criteria for these images, and more than 90% have a 95% pass-rate, nd ESTRO Forum 2013 with an average of 97.3% (see Figure 1 for an example of pass-rate vs. gantry angle result). Using this method, a problem with the gantry motor control with one linac at our centre was found, which was corroborated (albeit at a much higher time cost) by commercial VMAT QA products, further proving its utility in a clinical setting. Figure 1 . Chi results comparing EPID images to predicted images for each sub-arc during a complete VMAT delivery.
Conclusions:
The method provides a comprehensive and highly efficient pre-treatment verification of VMAT delivery using EPID. Dose delivery accuracy is assessed as a function of gantry angle to ensure accurate treatment. Individual Chi maps for small sub-arcs provide a useful tool for error diagnostics. Purpose/Objective: In volumetric-modulated arc therapy (VMAT) gantry speed, multileaf collimator configuration, and dose rate vary continuously during delivery. For a safe clinical implementation of VMAT, accurate 3D dose verification is essential but also complicated. In our department, EPID-based in vivo dosimetry using a semiempirical back-projection model is clinically employed to verify all VMAT treatments. The purpose of this study was to investigate the sensitivity of our 3D in vivo EPID dosimetry approach to detecting patient-related errors during VMAT delivery. Materials and Methods: Treatment planning of VMAT was performed using the SmartArc module of the Pinnacle treatment planning system. In order to assess the sensitivity of our EPID-based in vivo dosimetry method, patient-related errors were simulated by changing position and dimension of an anthropomorphic (Alderson) phantom. The phantom was irradiated using a 2-arc head-and-neck (6 MV), prostate (10 MV) and lung (10MV) VMAT technique. The errors comprised a vertical and horizontal phantom shift of 2 cm, a 10 degree rotation, and the addition of 1cm tissue-equivalent material. Dose distributions reconstructed from EPID images and the original planned dose distributions were compared using 3D γ evaluation using 3% dose difference relative to the maximum dose, and 3 mm distanceto-agreement as criteria. Results: Table 1 shows the 3D gamma evaluation of the total dose relative to the situation without errors. For the prostate treatment, the effect of the introduced errors is negligible, except that the reconstructed dose at the prescription point was 4.2% higher for a change in thickness of 1 cm. For the head-and-neck treatment, results for the gamma evaluation showed a larger sensitivity for the introduced errors. Also the dose difference at isocenter for the thickness error was larger: -7.8%. The results for the lung plan were similar to those for the prostate plan. Conclusions: Our verification results show that vertical and horizontal shifts and a rotation of the order of 2cm and 10 degree, respectively, do not result in significant deviations between EPID reconstructed and treatment plan dose distributions for both prostate and lung VMAT treatments. The head-and-neck VMAT treatments are more sensitive for position errors. With VMAT, EPID dosimetry is often not able to detect patient position discrepancies, and should be combined with
OC-0157 Sensitivity of EPID-based in vivo dosimetry to detect errors during VMAT delivery
